[ad_1]
<div id = "firstBodyDiv" data-bind-html-content-type = "article" data-bind-html-compile = "article.body" data-first-article-body = "
Depends on the drug "Vitracave" (Vitrakvi), to treat the genetic mutations of tumors, regardless of the type of disease or place of origin.
Scott Gottlieb, Commissioner of the US Commission, said that "This is an important step in the treatment of cancer because it treats it from its source and treats the gene base of cancerous tumors, regardless from the location of their origin in the human body. "
Gottlieb has confirmed that the new drug will help cancer patients to get proper treatment and to bring a drug "Vitracave" In the treatment of people with different tumors, but have common genetic mutations.
Dr. David Hayman, president of Sloan Kettering Cancer, a center for early drug development based in New York, said, "Traditionally, cancer has been treated according to the source of the cancerous tumor, but currently it will be treated anywhere in the body because you are treating the original gene that caused the tumor. "
The drug has actually been tested on humans and a child was cured a few months after taking the drug, which will be administered on two bodies, the first in tablets or capsules and the other in the form of a drug for children.
">
Vitrakvi depends on the treatment of genetic mutations of cancerous tumors, regardless of the type or location of the disease.
"The approval of the release and the introduction of this drug is an important step in the treatment of cancer because it treats it from its source and treats the gene base of cancerous tumors, regardless of the cancer." Location of their origin in the human body, "said Scott Gottlieb, commissioner of the FDA.
Gottlieb has confirmed that the new drug will help cancer patients get proper treatment. Vitracave helps treat people with different cancers, but their genetic mutations are common.
"Traditionally, cancer was treated at the base of the cancer source, but now the treatment will be applied anywhere in the body because you are treating the original gene that caused the tumor," said David Hayman, president of Sloan Kettering Cancer, a center for early drug development based in New York. "He said.
The drug has actually been tested on humans and a child was cured a few months after taking the drug, which will be administered on two bodies, one in tablet or capsule form and the other under form of children's medicine.
